Clinical trials: Diabetic Nephropathy Type 2
Diabetic Nephropathy, Chronic Kidney Disease
Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
Diabetic nephropathy has become the single most frequent cause of end-stage renal disease. On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these…
- Conditions
- Diabetic Nephropathy, Chronic Kidney Disease, Diabetes Type 2
- Trial name
- NCT00556465
- Testing
- N-acetylcysteine
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetic Nephropathies
Effect of Low Protein Diet in Preventing the Progression of Diabetic Nephropathy
Diabetic nephropathy is the leading cause of chronic kidney disease all the world in spite of progress in new treatment for diabetes and anti hypertensive drugs.
- Trial name
- LPD (NCT00448526)
- Testing
- low protein diet
- Sponsor
- Kanazawa Medical University
Diabetes Mellitus, Type 2, Diabetic Nephropathies
Cholesterol Metabolism in Plasma and Interstitial Fluid Among Subjects Undergoing Hemodialysis.
Because the atherosclerosis process partly occur in the intercellular space of the vessel wall, the determination of the constitution of lipoproteins in the interstitial fluid may expand the knowledge about the atherosclerosis…
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Nephropathies, Chronic Kidney Diseases
- Trial name
- NCT03921216
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska University Hospital
Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease
Proven therapy for DKD is primarily limited to RAAS blockers and SLGT2i. Weight reduction has the potential to become an additional and much needed treatment option.
- Conditions
- Diabetes Mellitus, Type 2, Kidney Disease, Chronic, Kidney Injury
- Trial name
- OBESE-DKD (NCT04626323)
- Testing
- Roux-en-Y gastric bypass, Best medical treatment
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2
Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus
The overarching goal of this study is to understand facilitators and barriers to self-care, develop and refine a culturally tailored intervention to improve clinical outcomes, quality of life (QOL), and self-care behaviors in…
- Conditions
- Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
- Trial name
- NCT05692388
- Testing
- Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Medical College of Wisconsin
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Diabetic Nephropathy
Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
1. The primary objective of this study was： in patients with type 2 diabetes and microalbuminuria who have been receiving stable treatment of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) for…
- Trial name
- NCT02035891
- Testing
- colchicine 0.5mg/d
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chongqing Medical University
Essential Hypertension, Type 2 Diabetes
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups…
- Conditions
- Essential Hypertension, Type 2 Diabetes, Nephropathy
- Trial name
- Hyper-Save (NCT06501651)
- Testing
- Sacubitril/Valsartan, Valsartan
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Sichuan Academy of Medical Sciences
Type 2 Diabetes, Type 2 Diabetes With Renal Manifestations
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
According to the different epidemiological studies in Mexico the prevalence of diabetic nephropathy is 9.1%-40% in diabetic patients, however the complication is subdiagnosed when we see the numbers of uncontrolled diabetics…
- Trial name
- NCT05378282
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital Juarez de Mexico
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study
This randomized study will test a behavioral intervention, based on social cognitive theory (SCT), to improve regimen adherence in three different groups of people with type 2 diabetes; (1) those with well controlled blood…
- Trial name
- ENHANCE (NCT00222846)
- Testing
- Attention control, Intervention
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- University of Pittsburgh
Diabetic Nephropathy Type 2, Biomarker
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD).
- Trial name
- NCT04931537
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Type 2 Diabetes, Diabetic Nephropathy
Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.
Hypertension is highly prevalent in type 2 diabetic patients (NIDDM) with nephropathy, and is the single most important determinant of the rate of renal function loss.
- Conditions
- Type 2 Diabetes, Diabetic Nephropathy, Hypertension, Sleep Apnea
- Trial name
- SAS (NCT01875341)
- Testing
- NCPAP; Nasal continuous positive airway pressure., NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Type 2 Diabetes Mellitus
Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients
Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect against diabetic nephropathy. We hypothesise that this is also the case in humans.
- Trial name
- NCT01664676
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- University of Aarhus
Type 2 Diabetes, Microvascular Function
The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes
Patients with type 2 diabetes have an increased risk of developing vascular complications. Microvascular dysfunction might be caused by the increased production of methylglyoxal under hyperglycaemic conditions.
- Conditions
- Type 2 Diabetes, Microvascular Function, Retinopathy, Diabetic, Nephropathy, Diabetic
- Trial name
- PYRAMID (NCT06376240)
- Testing
- Pyridoxamine 300mg per day
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Maastricht University Medical Center
Diabetic Nephropathies, Diabetes Mellitus, Type II
Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy
Background The relationship between long-term heavy lead exposure and chronic interstitial nephropathy is well recognized in the previous literatures.
- Trial name
- NCT00237952
- Testing
- EDTA chelating agents
- Where
- 2 sites in China
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Nephropathies
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
This study is a single center open-label randomized controlled trial designed to evaluate the efficacy of calcitriol plus losartan therapy in subjects with type II diabetes and macroalbuminuria.
- Trial name
- IDEAL (NCT02410005)
- Testing
- Calcitriol, Losartan
- Where
- 3 sites in United States, Qatar
- Volunteers
- 56 people
- Sponsor
- Weill Cornell Medical College in Qatar
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetic Nephropathy
Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy
The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.
- Trial name
- NCT01300273
- Testing
- Compound α-Ketoacid Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetic Kidney Disease
Non Diabetic Causes of Chronic Kidney Disease in Type 2 Diabetic Patients
Determination of the possible causes of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus with an atypical presentations of renal disease for proper management and thus improving renal outcome.
- Trial name
- NCT05021705
- Volunteers
- 60 people
- Sponsor
- Assiut University
Diabetic Nephropathy
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
This trial is randomized, placebo-controlled, double blind, double dummy, multi-centre trial. Screening period (4 week) Double blind treatment period (16 weeks)
- Trial name
- NCT01726816
- Testing
- Probucol 250mg/day, Probucol 500mg/day
- Where
- 16 sites in South Korea
- Volunteers
- 126 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.